United by our values

Sangeeta carries total work experience of 22 years in the pharmaceutical industry and HEOR with respect to project management, managed quarter wise planning for submission of dossiers (new product/ renewals). Following & conceptualizing Standard Operating Procedures, manuals & work instructions for operations, Insightful skills in leading employee training & development division by monitoring competency grids and identifying training needs for skill / competency up-gradation.

Previously associated with Meyer Organics (4.6 years), Raptakos, Brett & Co. Ltd (6 years) in research and development.

Lalit has total work experience of ten plus years in HEOR and Market Access who has worked on multiple disease areas (Pharma & Oncology). Expertise in managing end-to-end projects such as SLR/ TLR, Value Dossiers, Scientific HEOR Slide decks/ Abstracts/ Posters/ Manuscript writing.

Previously associated with Novartis Healthcare Pvt Ltd (6 years) and LCCI, Eli Lilly Services Pvt Ltd (1 year). Has authorship in several international manuscripts and abstracts/posters presented at conferences:

1. Model parameters influencing the cost-effectiveness of sacubitril/valsartan in heart failure: evidence from a systematic literature review, The European Journal of Health Economics 2022
2. A systematic review of the effectiveness and safety of pharmacological treatments in patients with systemic idiopathic juvenile arthritis (SJIA), EULAR Madrid, 12-15 June 2019
3. Systematic literature review on the incidence and prevalence of heart failure in children and adolescents, Pediatric cardiology, March 2019
4. Systematic literature review on the economic, humanistic, and societal burden of heart failure in children and adolescents, Expert review of Pharmacoeconomics & outcomes research, Oct 2019
5. Randomized controlled trials in heart failure with preserved ejection fraction (HFpEF) –A systematic review (SR) of included patient populations, 21st ISPOR Europe, 10-14 Nov 2018
6. A systematic review on the efficacy of pharmacological treatments in patients with heart failure with preserved ejection fraction (HFpEF), 21st ISPOR Europe, 10-14 Nov 2018

Ritesh has total work experience of nine plus years in HEOR and has worked on multiple disease areas (Pharma & Oncology). Expertise in managing end-to-end projects such as SLR/ TLR, Value Dossiers, Scientific HEOR Slide decks/ Abstracts/ Posters/ Manuscript writing

Previously associated with BresMed (Lumanity) Health Solutions (3.5 years), IQVIA (2 years) and Novartis Healthcare Pvt Ltd (1.5 years). Has authorship in several abstracts/posters presented at conferences:

1. Evidence review group (ERG) critique of Systematic reviews (SR) submitted to nice as Part of single technology appraisals (STA) or multiple technology appraisals (MTA) in the last three years, 18^th ISPOR Europe 2015, Milan, Italy
2. Economic burden of Myasthenia Gravis in the US: A literature review 23^rd ISPOR  USA 2015, Baltimore
3. Economic burden of Fragile X Syndrome in Europe and the US: A systematic literature review 21^st ISPOR Europe 2015, Barcelona, Spain

Inayat has a total work experience of 6 years in Pharmacovigilance and has expertise in managing multiple projects. She also has worked in academics and as a community pharmacist. Being a Pharmacovigilance person, she has experience in literature monitoring, ICSR processing, SDEA management, PSMF preparation, safety variation, safety data reconciliation, compliance monitoring, signal detection etc.
Previously associated with MacLeod’s Pharmaceuticals Pvt. Ltd.  and Clinexel Life Sciences Pvt. Ltd. . Has authored a few review articles.

Dr Kiran More, is a Neonatologist with 20+ years of experience in medical and safety monitoring. He has done MBBS and Doctor of Medicine (MD) in Pediatrics from University of Mumbai.

He is Australian Board-Certified Neonatologist with FRACP in Neonatal-Perinatal medicine, Global Clinical Scholars Research Training Program (GCSRT), Harvard Medical School, USA, CCPU- ASUM, Australia.

His core expertise are Advance Neonatal Care, complex critical newborns with surgical, cardiac problems, Neonatal Hemodynamic and extremely premature babies.

He is working as a Senior Medical Expert with SRS HEOR. Dr. Kiran More is experienced in providing expert clinical judgements in safety and pharmacovigilance and he also has understanding of treatments and therapeutic practices in India, MENA region, Canada, Europe, Australia etc.

Sharad has total eight years of experience in Intellectual Property Management and he holds an M. Pharm degree and Bachelor of Law.

He is having experience in Patent searches, landscaping, design around strategies, infringement analysis, patent challenges, IP support in patent litigations, patent drafting, prosecution, new product identification, and trademark related activities. He has worked extensively for patent searches and analysis for various markets such as US, Europe, Canada, India, Southeast Asia, Latam and among others.

Previously associated with Alembic Pharma’s JV Orbicular Pharma (3.3 years) and Zenvision Pharma (3.7 years).